Cristina Chang: The Importance of The New ET Treatments
Cristina Chang, Chief Medical Officer (CMO), Global at Harvest Integrated Research Organization (HiRO), shared a post on LinkedIn:
“What is essential thrombocythemia – and why are new treatments important?
Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm in which the bone marrow produces too many platelets.
Despite the high platelet count, patients face the seemingly contradictory risks of both dangerous blood clots and abnormal bleeding.
ET is commonly driven by mutations in JAK2, CALR, or MPL.
Patients may experience fatigue, headaches, dizziness, visual disturbances, night sweats, an enlarged spleen, or painful redness and burning in the hands and feet.
More serious complications include stroke, heart attack, deep-vein thrombosis, pulmonary embolism, and gastrointestinal bleeding.
Treatment is guided by age, mutation status, cardiovascular risk factors, and previous thrombosis.
It may include observation, low-dose aspirin, and cytoreductive therapy to control blood counts and reduce complications.
Because ET is a lifelong disease with a small risk of progression to myelofibrosis or acute myeloid leukemia, patients require long-term monitoring – and treatments that can address not only platelet counts but also the underlying disease biology.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge